Advertisement
Advertisement

CGTX

CGTX logo

Cognition Therapeutics, Inc. Common Stock

1.08
USD
Sponsored
-0.16
-12.90%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

1.10

+0.02
+2.31%

CGTX Earnings Reports

Positive Surprise Ratio

CGTX beat 9 of 17 last estimates.

53%

Next Report

Date of Next Report
Mar 18, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.08
Implied change from Q3 25 (Revenue/ EPS)
--
/
+33.33%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-52.94%

Cognition Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, CGTX reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.10 USD, resulting in a 41.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.78% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 33.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Cognition Therapeutics, Inc. Common Stock reported EPS of -$0.06, beating estimates by 41.18%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.78%, changed from $1.69 before the earnings release to $1.66 the day after.
The next earning report is scheduled for Mar 18, 2026.
Based on 5 analysts, Cognition Therapeutics, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement